Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NKTR-214||Bempegaldesleukin||NKTR-214 comprises IL2 bound to polyethylene glycol, which stimulates anti-tumor immune response, potentially resulting in decreased tumor growth (PMID: 26832745).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||osteosarcoma||not applicable||NKTR-214||Preclinical||Actionable||In a preclinical study, NKTR-214 treatment inhibited growth of primary tumor, regrowth after amputation, and lung metastasis in disseminated and orthotopic mouse models of osteosarcoma (AACR Annual Meeting 2019, Abstract 3210).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02869295||Phase I||NKTR-214||A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors||Completed|